Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback